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The humanised anti-epidermal growth factor receptor (EGFR) monoclonal antibody matuzumab (formerly EMD 72000) is active
against pancreatic cancer in preclinical studies. This phase I study assessed the safety and potential benefit of combined treatment
with matuzumab and standard-dose gemcitabine. Three groups of chemotherapy-naive advanced pancreatic adenocarcinoma
patients (n¼17) received escalating doses of matuzumab (400mg weekly, 800mg biweekly, or 800mg weekly) and gemcitabine
(1000mgm
–2 weekly in weeks 1–3 of each 4-week cycle). Toxicity, antitumour activity, pharmacokinetic (PK) parameters, and
pharmacodynamic (PD) markers in skin biopsies were evaluated. Severe treatment-related toxicities were limited to grade 3
neutropenia (n¼3), leucopenia (n¼1), and decreased white blood cell count (n¼1). Common study drug-related adverse events
were skin toxicities (grade 2¼6, grade 1¼7) and fever (grade 1¼4). Matuzumab inhibited phosphorylated EGFR and affected
receptor-dependent signalling and transduction; effects were seen even in the lowest-dose group. Pharmacokinetic data were
consistent with results of matuzumab monotherapy. Partial response (PR) or stable disease occurred in eight of 12 evaluated patients
(66.7%), with three PRs among six evaluated patients in the group receiving 800mg weekly. Matuzumab in biologically effective doses
with standard gemcitabine therapy appears well tolerated. The combination is feasible and may have enhanced activity.
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The 5-year life expectancy of a patient diagnosed with pancreatic
cancer is about 4% (Parkin et al, 1999). Gemcitabine therapy
provides some benefit and modestly improves survival compared
with fluorouracil, but median survival in patients with advanced
disease remains less than 6 months (Burris et al, 1997). Altered
expression or constitutive activation of the epidermal growth
factor receptor (EGFR/HER1/erbB1) commonly occurs in both
primary and metastatic pancreatic cancers and is often a critical
component in progressive growth and resistance to normal
mechanisms of cell death (Lemoine et al, 1992; Schmiegel et al,
1997; Xiong and Abbruzzese, 2002). Epidermal growth factor
receptor expression in pancreatic cancer has been correlated with
tumour aggressiveness (Tobita et al, 2003).
Matuzumab (formerly EMD 72000) is a humanised immuno-
globulin G1 (IgG1) monoclonal antibody to the human EGFR
(Kettleborough et al, 1991). Matuzumab binds the EGFR with high
affinity, competitively blocking natural ligand binding and
blocking receptor-mediated downstream signalling (Kettleborough
et al, 1991; Tabernero et al, 2003). In preclinical studies,
matuzumab demonstrated activity in the PAXF546 xenograft
model of human pancreatic cancer that expressed high levels of
EGFR and demonstrated almost complete resistance to clinically
available chemotherapeutic drugs (Burger et al, 2003). Also,
combining matuzumab with gemcitabine enhanced the effects of
gemcitabine in the L3.6pl model of gemcitabine-sensitive pancrea-
tic cancer (Amendt et al, 2003). In these studies, antitumour effects
were mediated partly by direct inhibition of tumour growth and
partly by inhibition of tumour-induced angiogenesis. In addition,
because matuzumab is an IgG1 antibody to the EGFR able to
mediate antibody-dependent cellular cytotoxicity, additional
cytotoxic mechanisms may be involved in its effects in pancreatic
cancer (Lo et al, 2003; Graeven et al, 2004).
A phase I clinical trial with matuzumab demonstrated that it is
well tolerated as a single agent at doses between 400 and 1600mg
administered weekly, biweekly, or every 3 weeks (Vanhoefer et al,
2004). Dose-limiting toxicities (DLTs) occurred at 2000mg on a
weekly schedule and consisted of grade 3 headache and fever. Skin
reactions, common with anti-EGFR agents (Thomas and Grandis,
2004), did occur with matuzumab, but results to date suggest that
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sthey are less severe than with other anti-EGFR agents and are
restricted to grade 1 and 2 severity (Kollmannsberger et al, 2003;
Salazar et al, 2004; Vanhoefer et al, 2004). Pharmacokinetic (PK)
and pharmacodynamic (PD) results of the phase I study showed
that matuzumab has predictable PKs at clinically relevant doses
and that treatment with matuzumab blocks growth factor
signalling through EGFR with a weekly dose of 800mg as
effectively as with doses of 1200 or 1600mg.
This study was undertaken to determine whether matuzumab
could be safely administered at biologically effective doses (800mg
weekly) with a standard regimen of gemcitabine to previously
untreated patients with advanced pancreatic cancer and to study
the PD and PK properties of matuzumab in this setting. In the
absence of extensive prior clinical experience with matuzumab in
combination with chemotherapeutic agents, the matuzumab dose
was escalated through three treatment cohorts to the target weekly
dose of 800mg.
PATIENTS AND METHODS
Eligibility
Eligible patients had confirmed untreated stage III or IV pancreatic
cancer, measurable by computed tomography (CT) or magnetic
resonance imaging (MRI) and available tumour tissue for the
determination of EGFR expression. Age X18 years, Karnofsky
performance status X60%, life expectancy 412 weeks, and
adequate organ and marrow function (white blood cell (WBC)
count 43 10
9l
 1, haemoglobin levels 49gdl
 1, platelet counts
4100 10
9l
 1, liver enzyme levels o2.5 upper limit of normal
(ULN), and creatinine levels o1.5 ULN) were required. Pregnant
or lactating females were ineligible, and females and males of
childbearing age were required to use reliable birth control
methods. Other exclusion criteria included treatment with any
nonpermitted medication, the presence of brain metastases, active
and uncontrolled infections, or uncontrolled severe organ
dysfunction. All patients provided written informed consent. The
ethical committees of the participating institutions approved the
study. The study followed the Declaration of Helsinki and good
clinical practice guidelines.
Study design and treatment
The study (Protocol EMD 72000-021) was designed as a phase I,
noncontrolled, nonrandomised, open-label study to evaluate the
tolerability of matuzumab plus gemcitabine in patients with
previously untreated advanced pancreatic cancer. Secondary
objectives were to confirm previous PD findings about matuzumab-
induced inhibition of EGFR-mediated cell signalling in the skin
and potentially relate it to response, and to form a preliminary
assessment of the activity of the matuzumab–gemcitabine
combination in advanced pancreatic cancer. Other objectives were
to evaluate matuzumab PKs and to confirm PK and PD results
from previous studies. The study was conducted at two centres
in Germany: the University-Hospital of Schleswig-Holstein in
Kiel and Ruhr University in Bochum.
Matuzumab was supplied by Merck KGaA (Darmstadt,
Germany). Matuzumab was administered to three patients in each
dose group in an escalating, sequential manner in combination
with a fixed dose of gemcitabine (1000mgm
–2 once weekly for 3
weeks, followed by a 1-week rest). Three matuzumab dose levels
were planned on the basis of the prior studies (Vanhoefer et al,
2004): group I, 400mg once weekly; group II, 800mg every 2
weeks; and group III, 800mg once weekly. If a DLT was observed
in one of the three patients at one dose level, an additional three
patients were enrolled at this dose level. If no DLT was observed at
a given dose level, three patients were enrolled at the next dose
level. If no DLT was observed in the first three patients at the
highest dose (800mg once weekly), three additional patients were
enrolled and dose escalation was stopped. A maximum of 18
patients (six at each dose level) was planned. No intrapatient dose
escalation was permitted.
During the first 8 weeks of study (two 4-week treatment cycles),
data were collected to assess safety, PKs, and tumour responses. In
a subset of patients who provided additional informed consent, PD
studies were also conducted on skin biopsy specimens obtained
before treatment and at the end of the first treatment cycle. After 8
weeks, treatment was discontinued in patients with progressive
disease. Patients with stable or responding disease continued
treatment until disease progression or unacceptable toxicity.
Matuzumab (Merck KgaA, Darmstadt, Germany) lyophilised in
glass vials containing 200mg antibody was reconstituted in 20ml
of sterile water, diluted with 0.9% (wtvol
 1) normal saline solution
to a total volume of 250ml, and administered as a 1-h intravenous
infusion. Patients were observed for 1h after completion of the
matuzumab infusion before being given the gemcitabine infusion.
Commercially available gemcitabine was administered as a 30-min
intravenous infusion.
EGFR expression
Before entering the study, EGFR expression was established using
a two-step immunohistochemical staining procedure on either
archived tumour material or a recently obtained formalin-fixed,
paraffin-embedded tumour biopsy. A commercial EGFR staining
kit was used (Dako pharmDx, Dako Corporation, Glostrup,
Denmark) and the manufacturer’s recommended procedures were
followed. This kit is approved by the US FDA as a type I in vitro
diagnostic for use with routinely processed, paraffin-embedded
specimens after fixation in 10% buffered neutral formalin. After
proteolytic digestion, the samples are stained with a murine
anti-human EGFR monoclonal antibody (Clone 2-18C9). The
visualisation system is a secondary goat anti-mouse antibody and
horseradish peroxidase. Results were interpreted by light micro-
scopy. Tumours were considered positive if any membrane
staining was observed in 10% or more of tumour cells.
Evaluation of toxicities and response
Adverse events (AEs) were assessed weekly throughout the study,
and toxicities were graded according to the National Cancer
Institute Common Toxicity Criteria (NCI CTC; version 2.0). Dose-
limiting toxicity was assessed only during cycles 1 and 2, and only
possibly drug-related AEs were considered in defining the DLT.
The maximum-tolerated dose (MTD) was defined as the dose level
below that at which the DLT was observed in two or more of a
maximum of six patients. Tumour response was assessed by CT or
MRI of the target lesion(s) every 8 weeks and was classified as
complete response (CR), partial response (PR), stable disease (SD)
or progressive disease (PD) according to Response Evaluation
Criteria in Solid Tumours (RECIST).
Pharmacokinetics
Serum was collected at several time points to assess pharmaco-
kinetic parameters (maximum serum concentration (Cmax), area
under the serum concentration-versus-time curve (AUC), half-life
(t1/2)) of matuzumab. For dose groups I and III (matuzumab
400mg weekly or 800mg weekly), 5ml of venous blood was drawn
before matuzumab administration, at 1, 2, 5, 48, and 96h after
the start of the first and fifth infusions and at 168h thereafter
(before the infusions on weeks 2 and 6). Predose samples were also
collected before infusions 3, 4, 7, and 8. For dose group II
(matuzumab 800mg every 2 weeks), blood was drawn at the same
time points. Serum concentrations of matuzumab were determined
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sby Merck KGaA using a validated sandwich enzyme-linked
immunosorbent assay with a lower limit of quantification (LLQ)
of 0.5mgml
 1, as described previously (Vanhoefer et al, 2004).
The PK parameters of matuzumab were calculated according
to noncompartmental methods using the PK software program
Kinetica, version 4.1.1. The following parameters were determined
from the serum concentration data of matuzumab: Cmax; time to
reach Cmax (tmax); elimination t1/2; AUC up to time t, where t is the
last time point at which a serum sample shows a concentration
above the LLQ (AUC0 t); AUC until infinity (AUC0 N), equivalent
to AUC0 tþAUCextra, where AUCextra represents an extrapolated
value obtained by CT/lz, where CT is the last measured serum
concentration above LLQ; volume of distribution during terminal
phase (Vz); and total-body clearance of drug from serum (CL).
Pharmacodynamics
To assess the impact of matuzumab on signalling through the
EGFR pathway, skin punch biopsy specimens were obtained from
a subset of patients who provided additional informed consent.
Biopsies were obtained before and after the first cycle (4 weeks)
of treatment. Immunohistochemical analyses for pretreatment
and on-treatment levels of basal EGFR (antibody¼Dako, Clone
2-18C9, 1:1), phosphorylated EGFR (pEGFR) (Chemicon Inter-
national Inc., Hampshire, England; Clone 174, 1:1000), phosphory-
lated p42/p44 mitogen-activated protein kinase (MAPK) at Thr202
and Tyr204 (pMAPK) (CST, #9101, 1:80), Ki-67 (Dako; MIB1,
1:100), p27
kip1(Dako, Clone SX53G8, 1:100), and checkpoint
kinase-1 (CK-1) were performed in paraffin-embedded sections, as
described recently. Paired tissue sections known to be positive for
the antigen were included in each analysis, and negative control
sera were used on duplicate sections of the test materials (Albanell
et al, 2001; Baselga et al, 2002). Slides were counterstained using
Mayer’s haematoxylin. The percentage of keratinocytes stained for
each antibody was calculated based on counting the staining
results in E1250 cells in interfollicular epidermis and in all the
cells in the hair follicles (if present). Histopathologic scoring of
stained cells was performed in a blinded manner. Pharmaco-
dynamic studies were supervised by Dr F Rojo at the Vall d’Hebron
University Hospital, Barcelona, Spain.
RESULTS
This open-label nonrandomised dose-escalation study enrolled 17
patients with previously untreated advanced pancreatic adenocar-
cinoma; patient characteristics are shown in Table 1. Epidermal
growth factor receptor expression was confirmed by immuno-
histochemistry in tumours from 16 patients; no tumour tissue was
available for EGFR analysis for one patient.
The dosing schedule is shown in Figure 1. Among the 17 patients
who entered the study, 12 completed at least two cycles (8 weeks)
of treatment (phase A). Among patients not completing two cycles
of treatment, four discontinued because of AEs and disease
progression, and one owing to AEs alone. Nine patients received
treatment after the second cycle (phase B) until disease progres-
sion (7) or death (2). The median duration of exposure to
matuzumab was 99 days for the 17 patients in the treated
population. A median of eight (1–45) infusions was administered.
Study drug-related AEs by NCI CTC grade and matuzumab dose
are presented in Table 2. In the three treatment groups, one patient
(400mg matuzumab weekly) developed grade 3 neutropenia with
a mild fever that did not meet the requirements for DLT
(neutropenia with fever 4401C). Among the 17 patients in the
study, there were five grade 3 haematologic AEs; none met the
requirement for DLT. There were no other drug-related grade 3,
or grade 4 AEs. Serious AEs occurred in 12 of 17 patients (70.6%),
but none was drug related. Grade 3 nontreatment-related AEs
occurring in more than one patient included fever (n¼2),
cholangitis (n¼3), hypokalaemia (n¼2), increased lactic dehy-
drogenase levels (n¼2), and other increased liver enzyme levels
(n¼12). Grade 4 nontreatment-related AEs included cachexia,
increased gamma-glutamyltransferase, and increased bilirubin
in three of the five patients treated at 400mg weekly with
gemcitabine. Although it was not considered drug related by the
investigator, a case of grade 4 Guillain–Barre ´ syndrome with
quadriplegia in a patient treated with matuzumab 800mg weekly
with gemcitabine was classified as possibly treatment related by
the sponsor of the study. Three patients died owing to progressive
disease while on treatment p30 days since the last dose (one
patient at each dose level). The most frequent drug-related AEs
included grade 1/2 skin toxicity. Although the occurrence of skin
Table 1 Patient characteristics
400mgweek
 1
(n¼5)
800mgq2week
 1
(n¼4)
800mgweek
 1
(n¼8)
Total
(n¼17)
Age – median in years (range) 64.0 (60–70) 55.5 (39–72) 69.5 (57–82) 64.0 (39–82)
Gender – male/female 4/1 1/3 4/4 9/8
Months from initial diagnosis to screening – mean (SD) 1.2 (0.84) 1.6 (0.71) 3.1 (3.19) 2.2 (2.35)
Stage of tumour
III 1 1 1 3
IV 4 3 7 14
Results of EGFR testing
Negative 0 0 0 0
Positive 4 4 8 16
Missing 1 0 0 1
Karnofsky performance status at screening – median % (range) 80 (60–100) 75 (70–80) 80 (70–90) 80.0 (60–100)
EGFR¼epidermal growth factor receptor; SD¼stable disease.
Cycle 1 Cycle 2
Days 1 8 15 22 1 8 15 22
Phase A Phase B //
//
Matuzumab
Gemcitabine
All groups 1000 mg/m
2
Group I 400 mg qw
Group II 800 mg q2w
Group III 800 mg qw
Figure 1 Dosing scheme for matuzumab and gemcitabine in the three
groups in phases A and B.
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stoxicity was dose related, severity did not appear to be related to
dose.
Pharmacokinetic results are shown in Table 3, and serum
concentration profiles in Figure 2, showing the relative differences
among the dose groups. Serum samples were collected from all 17
patients but not at all time points. For all patients, a sufficient
number of serum samples were available to allow calculation of PK
parameters after first infusion (cycle 1). In cycle 2 (weeks 5–8), 12
patients (three at 400mg weekly, three at 800mg biweekly, six at
800mg weekly) were included in the PK population, mainly
because of discontinuation of patients. Peak serum concentrations
were reached within 1–3h after the start of the 1-h matuzumab
infusion (Table 3). Exposure as indicated by the AUC and Cmax
showed nearly dose-proportional increases, with evidence of
accumulation from weeks 1 to 5. Half-life tended to increase,
and clearance appeared to decrease with matuzumab dose and the
number of doses. Differences between the two 800-mg dose groups
could be explained by the longer sampling interval for the
biweekly-dose group. During week 5 at the 800-mg-weekly dose
level, the mean half-life of matuzumab in four evaluable patients
was about 8 days (196h). The volume of distribution was about 5l,
consistent with the expected tissue distribution of a monoclonal
antibody.
Results of PD studies on paired biopsy specimens of normal skin
obtained from the same area of skin before treatment and after
the first 4-week treatment cycle are shown in Figure 3. Separate
permissions were sought to obtain the biopsy specimens, and
10 patients participated, with three in the 400-mg-weekly, two in
the 80-mg-biweekly, and five in the 800-mg-weekly groups. For
reasons related to the amount of tissue in each biopsy specimen,
not all specimens could be tested for all markers. At all doses,
matuzumab therapy inhibited signalling through EGFR (pEGFR)
and the MAPK pathway, reduced the proportion of cycling cells
in the biopsy specimen (Ki-67), and increased the expression of
cell cycle inhibitory molecules (p27
kip1, CK-1). Matuzumab did not
affect the expression of EGFR, but its activation (pEGFR) was
reduced in all specimens (mean 64.2%) after treatment. Activation
of MAPK was reduced by a mean of 81.0% in eight paired biopsy
specimens, and expression of Ki-67 in the basal keratinocytes
was reduced by a mean of 65.3% in the 10 paired specimens. In
10 paired specimens, expression of the p27
kip1 cyclin-dependent
kinase inhibitor was increased from a mean basal level of 3–26.5%
and that of CK-1 was increased from 4.7–37.3%.
Table 3 Pharmacokinetic parameters of matuzumab in combination with gemcitabine
Cmax (lgml
 1) tmax (h) AUC0 N (hlgml
 1) AUC0 t (hlgml
 1) AUCextra (%) t1/2 (h) CL (lh
 1) Vz (l)
Dose Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
400mgweek
 1
Week 1 (n¼4–5) 101.2 20.8 1.6 0.9 10228 1865 6988 1865 31.2 10.8 106.4 33.2 0.041 0.013 6.22 2.32
Week 5 (n¼3) 138.0 7.0 1.0 0.0 24698 3626 14269 833 41.2 11.1 132.9 37.3 0.0281 0.0017 5.43 1.73
800mgq2week
 1
Week 1 (n¼4) 208.5 44.2 2.0 0.8 37657 15289 26730 8212 25.8 12.6 184.4 72.5 0.025 0.013 5.98 1.86
Week 5 (n¼3) 303.3 21.5 2.0 1.7 78704 344238 45695 12328 37.6 15 260.2 105.7 0.0186 0.006 6.46 1.42
800mgweek
 1
Week 1 (n¼7–8) 212.1 41.2 2.1 1.3 27854 9226 16356 3433 38.7 11.4 134.6 43.7 0.0317 0.0108 5.69 1.35
Week 5 (n¼4–6) 352.2 38.8 2.9 1.7 96133 29976 42247 5961 54 10.4 196.0 55.2 0.0192 0.0029 5.36 1.28
AUC0 N¼area under the serum concentration-versus-time curve until infinity; AUC0 t¼area under the serum concentration-versus-time curve up to time t, where t is the last
time point at which a serum sample shows a concentration above the lower limit of quantification (LLQ); AUCextra¼AUC from time t to infinity given as percentage from
AUC0 oo; tmax¼time to reach Cmax;C L ¼total body clearance of drug from serum; Cmax¼maximum serum concentration; SD¼stable disease; t1/2¼elimination half-life;
Vz¼volume of distribution during terminal phase.
Table 2 Drug-related adverse events by NCI CTC grade
All (n¼17)
Grade 3
Leucopenia 1
Neutropenia 3
WBC decreased 1
Grade 2
Leucopenia 2
Thrombocytopenia 2
Nausea 2
WBC count decreased 1
Skin disorders 6
Hypotension 1
Grade 1
Fever 4
Thrombocytopenia 1
Headache 1
Skin disorders 7
Folliculitis 1
DLT¼dose-limiting toxicity; NCI CTC¼National Cancer Institute Common
Toxicity Criteria; WBC¼white blood cell. DLT was defined as grade 3 or 4
nonhaematologic toxicities (excluding headache, alopecia, nausea, vomiting, skin
reactions, and fever above 401C for less than 24h); grade 4 nausea, vomiting, fever
above 401C sustained for more than 24h; grade 3 or 4 neutropenia associated with
complications (e.g. neutropenic fever); grade 4 thrombocytopenia, toxicity-related
discontinuation of treatment for more than 1 week within the first two treatment
cycles.
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Figure 2 Mean serum concentration-versus-time curves of matuzumab.
In all, 17 patients were assessable in week 1, and 12 patients were
assessable in week 5.
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sAmong the 12 patients evaluated for response after the second
treatment cycle (8 weeks, phase A), PRs were seen in two of six
patients (33%) in the group receiving 800mg weekly, and six
patients with SD were distributed across three dose groups, with
two at 400mg weekly, one at 800mg biweekly, and three at 800mg
weekly. Best overall response after the second treatment cycle
included the three PRs and five SDs, as in phase B, one patient in
the group receiving 800mg weekly with SD at the 8-week
evaluation developed a sustained response. Median survival among
the 17 patients was 3.7 months (range, 0.4–12.2 months).
DISCUSSION
This phase I study showed that matuzumab at a biologically
effective dose of 800mgweek
–1may be given safely with standard
gemcitabine therapy to patients with advanced pancreatic cancer.
Grade 3 treatment-related cases (total 5), including leucopenia
(n¼1), neutropenia (n¼3), and decreased WBC count (n¼1),
occurred in the study, but their occurrence was unrelated to the
matuzumab dose. There were 13 incidents at all dose levels of
grade 1 or 2 skin toxicities. Adverse events in this study were
consistent with those seen in other single-agent matuzumab
studies (Vanhoefer et al, 2004). No DLTs were observed, which
is also in agreement with previous work that established the MTD
of single-agent matuzumab as 1600mg on a weekly schedule
(Vanhoefer et al, 2004).
Rash is the most common toxicity reported in patients treated
with the anti-EGFR monoclonal antibodies cetuximab (Needle,
2002) and panitumumab (Schwartz et al, 2002), and in patients
treated with the EGFR tyrosine kinase inhibitors gefitinib (Baselga
et al, 2002) and erlotinib (Hidalgo et al, 2001), and its occurrence
with these agents is occasionally severe. In this study, the severity
of skin toxicity was limited to grades 1 and 2, with five of six grade
2 events observed with the lowest (400mg weekly) dose and five of
seven grade 1 events observed with the highest (800mg weekly)
dose. The pathophysiologic basis of skin rash in patients treated
with EGFR signalling inhibitors is not clear.
Skin has been used as a surrogate for tumour in measuring the
molecular effects of EGFR-targeted agents on EGFR, the ability of
EGFR to transmit signals to kinases downstream in the signalling
cascade and the responses mediated through EGFR, cell cycle
progression and proliferation (Salazar et al, 2004; Tan et al, 2004).
In this study, the molecular effects of matuzumab treatment on
EGFR signalling were investigated in basal keratinocytes in skin
biopsy specimens obtained before antibody treatment and on day
28 immediately before the fifth weekly dose. After the first cycle of
matuzumab treatment, there was no effect on EGFR expression in
basal keratinocytes, but EGFR signaling (pEGFR, pMAPK) was
substantially reduced, the cellular growth fraction (Ki-67) was
decreased to a similar extent, and accordingly, expression of cell
cycle inhibitors was markedly increased. Tissue biopsies were
obtained largely from patients receiving the highest matuzumab
dose (800mg weekly), but similar decreases in pEGFR, pMAPK,
and Ki-67, and increases in p27
kip1 and CK-1 were seen in biopsies
from patients treated with lower doses. In a preceding study in
which single-agent matuzumab (800, 1200, and 1600mg) was
administered on a weekly basis, highly significant changes in
pEGFR, pMAPK, Ki-67, and p27
kip1 expression were seen in skin
biopsies obtained at day 28, but no quantitative differences were
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% Basal Ki-67 % Basal p27 % Basal CK-1
% Basal pEGFR % Basal pMAPK
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Figure 3 Percentage of basal keratinocytes expressing epidermal growth factor receptor (EGFR; n¼10 patients), phosphorylated EGFR (pEGFR, n¼9),
phosphorylated p42/p44 mitogen-activated protein kinase (pMAPK) (n¼8), Ki-67 (n¼10), p27 (n¼10), and CK-1 (n¼10) determined by
immunohistochemistry on pretreatment and week 4 skin biopsy specimens. Individual results are shown. Blue lines refer to patients who received
matuzumab at 400mg weekly, red lines 800mg q 2 weeks, and green lines 800mg weekly.
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sapparent among the three dose groups (Vanhoefer et al, 2004) with
respect to any of these markers, and complete abrogation of
pEGFR, pMAPK, and Ki-67 expression was not achieved even
with the highest doses. The findings of the earlier study and the
concordant results of the current study support the selection of
800mg weekly as the optimal matuzumab dose for combination
with standard gemcitabine therapy.
Pharmacokinetic data gave no indication that concurrent
administration of matuzumab and gemcitabine affects the PKs of
matuzumab. The PK values obtained are consistent with those
obtained in matuzumab monotherapy studies (Tillner et al, 2003;
Vanhoefer et al, 2004). As demonstrated in this and other studies,
matuzumab PKs are predictable, although clearance is affected by
the antibody dose, particularly at doses below 800mg. A PK model
for this dose effect proposes parallel elimination pathways for the
antibody, one of which is saturable at the lower doses (Tillner et al,
2003). The half-life of matuzumab may be underestimated in this
study, as the ratio of the sampling period to the calculated half-life
was small, which could affect model-independent calculation of PK
parameters. AUC0 N and half-life should be re-evaluated with an
appropriately long sampling period.
Assessment of response was not a primary study objective, but it
is worth noting that by the end of the second 4-week cycle, eight of
the 12 evaluable patients benefited, with partial tumour responses
in two of six patients (33%) in the group receiving 800mgweek
–1
and stabilisation of the disease in eight other patients across the
three dose groups. One patient with SD at the end of the second
4-week cycle had a partial tumour response after the third cycle.
Encouraging findings have also been reported with the combina-
tion of gemcitabine and the anti-EGFR chimeric monoclonal
antibody cetuximab in the first-line treatment of patients with
advanced pancreatic cancer (Xiong et al, 2004). The study was
similar to ours, except that the cetuximab study was a phase II
design and the initial 7 weeks of gemcitabine were administered
without rest. Among 41 patients, there were five PRs (12.2%) and
26 had SD. Median overall survival was 7.1 months with 31.7%
1-year survival, results somewhat better than those expected with
gemcitabine alone (Burris et al, 1997).
This study shows that in patients with advanced pancreatic
cancer, the combination of matuzumab and gemcitabine is well
tolerated, with predictable PKs. In addition, weekly doses of
matuzumab of 800mg inhibited EGFR signalling and downstream
effects associated with EGFR stimulation in skin biopsies.
Responses in two of six patients treated with 800mg weekly and
disease stabilisation in an additional eight subjects across all
dose groups suggest that a phase II evaluation of this regimen in a
larger number of patients with advanced pancreatic cancer is
warranted.
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